title: [Disordered alpha 2-adrenoreceptor function in hemodialysis patients with renal anemia--a possible cause of increased blood pressure in relation to recombinant human erythropoietin?].
abstract: Nine patients on maintenance hemodialysis and transfusion-demanding renal anemia (group A) were treated with rHuEPO 120 IU/kg i.v. three times per week. Hemoglobin-content was raised from 7.2 +/- 0.9 to 10.4 +/- 0.8 g/dl. In all patients blood pressure rose, three patients developed arterial hypertension. Mean diastoloic blood pressure was 66 +/- 12 and 78 +/- 16 mmHg (p less than 0.001) before and after rHuEPO. Rise in blood pressure was accompanied by a significant fall in plasma-noradrenaline-levels (from 498 +/- 100 to 383 +/- 75 pg/ml; p less than 0.05) and alpha 2-adrenoceptor-density (from 574 +/- 76 to 384 +/- 49; p less than 0.05). Compared to nine patients on maintenance hemodialysis and hematocrit over 30% (group B), patients with severe renal anemia (group A before treatment) had higher densities of alpha 2-adrenoceptors (574 +/- 76 vs. 218 +/- 32; p less than 0.001) despite higher plasma-noradrenaline-levels (498 +/- 100 vs. 399 +/- 63; n.s.). We suppose a anemia-related disturbance of alpha 2-receptor-function with the result of abolished receptor down-regulation and impaired vascular reagibility to vasoconstricting stimuli. With the correction of anemia receptor-function improves, receptor down-regulation as well as vascular reagibility is re-established resulting in augmented vascular resistance and higher blood pressure.
authors.affiliation: Medizinische Klinik II, Universität Köln.
authors.forename: R
authors.initials: R
authors.lastname: Müller
authors.forename: H M
authors.initials: HM
authors.lastname: Steffen
authors.forename: R
authors.initials: R
authors.lastname: Brunner
authors.forename: M
authors.initials: M
authors.lastname: Pollok
authors.forename: C A
authors.initials: CA
authors.lastname: Baldamus
authors.forename: W
authors.initials: W
authors.lastname: Kaufmann
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000503:physiopathology* / Q000628:therapy*; D001794:Blood Pressure / Q000502:physiology; D001809:Blood Viscosity / Q000502:physiology; D004837:Epinephrine / Q000097:blood; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006400:Hematocrit; D006452:Hemoglobinometry; D006801:Humans; D006973:Hypertension / Q000503:physiopathology*; D007676:Kidney Failure, Chronic / Q000503:physiopathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D011941:Receptors, Adrenergic / Q000502:physiology*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D006435:Renal Dialysis; D014655:Vascular Resistance / Q000502:physiology
chemical_list: D011941:Receptors, Adrenergic; D011994:Recombinant Proteins; D004921:Erythropoietin; D009638:Norepinephrine; D004837:Epinephrine
vernacular_title: Gestörte alpha 2-Adrenozeptorfunktion bei Hämodialysepatienten mit renaler Anämie--eine mögliche Ursache der Blutdrucksteigerung unter rekombinantem humanem Erythropoietin?